Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

McKinsey
Boehringer Ingelheim
Baxter
Merck
Medtronic
Harvard Business School

Last Updated: December 8, 2019

DrugPatentWatch Database Preview

Patent: 5,876,942

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 5,876,942
Title: Process for sexing cow embryos
Abstract:A rapid, highly reproducible and sensitive technique has been successfully developed for sexing the cow embryos, by method of polymerase chain reaction (PCR) against the amelogenin (bAML) genes located on both X- and Y-chromosomes of the Holstein dairy cattle. Results from DNA sequence analysis showed that there was only 45% homology between the intron 5 of AMLX and AMLY genes. Based on these sequences a pair of sex-specific primers, pbAML5XY(+) and pbAML5XY (-),were designed allowing to amplify a single fragment of 476-bp from the female cattle and two fragments of 476-bp and 341-bp from the male ones, respectively. The most important feature is that the precise sensitivity of sex-determination was confirmed to be reached as minimum template as trace amount of genomic DNA content in either a single lymphocyte or a single blastomere isolated from cow embryo at day-6 to day-7. Moreover, neither those of complicated procedures for purifying the DNA prior the PCR nor any extra pair of primers for serving as internal control is thought to be essential and the sex-determination of over hundred embryos can be completed at once within 4hrs.
Inventor(s): Cheng; Winston Teng-Kuei (Taipei, TW), Chen; Chuan-Mu (Tai Chung, TW), Hu; Che-Lin (Taipei, TW), Wang; Chih-Hua (Taipei, TW), Choo; Kong-Bung (Taipei, TW)
Assignee: National Science Council of Republic of China (Taipei, TW)
Application Number:08/899,811
Patent Claims:see list of patent claims

Details for Patent 5,876,942

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Schering INTRON A interferon alfa-2b VIAL 103132 003 1986-06-04   Start Trial National Science Council of Republic of China (Taipei, TW) 2039-02-26 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 002 1986-06-04   Start Trial National Science Council of Republic of China (Taipei, TW) 2039-02-26 RX search
Schering INTRON A interferon alfa-2b VIAL 103132 001 1986-06-04   Start Trial National Science Council of Republic of China (Taipei, TW) 2039-02-26 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim
Colorcon
Merck
McKinsey
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.